Chronic Kidney Disease (CKD)
Conditions
Interventions
Oral administeration of olmesartan (20 mg/day) once in the morning
Sponsors
Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: To be eligible for the study is: 1) 6 g/day of salt intake at least 1 week before enrollment, 2)CKD patients according to K/DOQI criteria, 3) necessity of olmesartan therapy for CKD treatment, 4) documented informed consent.
Exclusion criteria
Exclusion criteria: Exclusion criteria is as follows: 1) receiving angiotensin receptor blocker, angiotensin converting enzyme inhibitor or diuretics for >2 months, 2) contraindication for the study drug, 3) presence or possibility of pregnancy, 4) HbA1c 9.0% or more, 5) GOT >100, GPT >85, 6) secondary hypertension , 7) accelerated or malignant hypertension (progressive renal dysfunction with diastolic BP of 120-130 mmHg or more), 8) serious congestive heart failure, coronary diseases, arrhythmia, or systemic diseases, 9) nephrotic syndrome with marked edema, or 10) any reason for eligibility suggested by the attending doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Temporal relationship between night-time BP reduction and daytime natriuresis increase during the first 3 days under the olmesartan treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Glomerular filtration rate, urinary excretion rates of albumin, potassium and chloride. | — |
Countries
Japan
Contacts
Public ContactMichio Fukuda
Nagoya City University Graduate School of Medical Sciences Department of Cardio-Renal Medicine and Hypertension
Outcome results
None listed